NOVADIP Biosciences
Business Services · Belgium · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Rue Granbonpré 11, Mont-Saint-Guibert, W...Phone Number
+32 10779220Website
www.novadip.comRevenue
$9.5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About NOVADIP Biosciences
Novadip is a spin-off company from Université Catholique de Louvain (UCLouvain) and St. Luc University Hospital. The creation of Novadip was supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II. Using the company's unique 3M3 tissue regeneration platform, which utilizes adipose-derived stem cells within a 3-dimensional extracellular matrix, to drive multiple product classes, Novadip’s mission is to provide innovative solutions for patients with limited or no effective treatment options.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NOVADIP Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if NOVADIP Biosciences is spiking on competitors!
Earning: See what the market has to say on NOVADIP Biosciences recently announced quarterly report
Product Launch: Get notified when NOVADIP Biosciences launches new products
Congratulate Masked Content for being promoted to Masked Content at NOVADIP Biosciences
Funding: Get notified immidiatlly once NOVADIP Biosciences has new funding data
Website visits: Recent activity has been detected on your website
Click to see if NOVADIP Biosciences had a recent Job posting/layoffs
NOVADIP Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if NOVADIP Biosciences has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at NOVADIP Biosciences
Find 3 more new buyers
Company Profile Activity
Activity Insights
NOVADIP Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NOVADIP Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NOVADIP Biosciences.
NOVADIP Biosciences financials insights
Gather financial insights about NOVADIP Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$31.3M
2022
Series B
$40M
NOVADIP Biosciences Tech Stack
A closer look at the technologies used by NOVADIP Biosciences
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
NOVADIP Biosciences News & Media
Novadip appoints Drew Trivisonno to the board of directors to drive financial and business ...
Seasoned financial executive with over 30 years’ experience – including senior management of orthopedic startups – to support Novadip in its financing rounds and expansion into US orthopedics marketMont Saint-Guibert, Belgium, January 9, 2025 – Novadip Biosciences, a clinical stage biotechnology company specializing...Novadip reports promising interim results from its first-in-human proof-of-concept trial with ...
At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete boneNovadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs
1st US patient treated with an autologous cell-based product (NVD-003) in a rare pediatric disease Full enrollment of patients on track for year-end completion in allogeneic cell-derived product (NVD-X3) trial in patients with a distal radius fracture following trauma MONT SAINT-GUIBERT,...Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs
1st US patient treated with an autologous cell-based product (NVD-003) in a rare pediatric disease Full enrollment of patients on track for year-end completion in allogeneic cell-derived product (NVD-X3) trial in patients with a distal radius fracture following trauma MONT SAINT-GUIBERT,...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding NOVADIP Biosciences
Sign Up For FreeTo access detailed company insights
Novadip is a spin-off company from Université Catholique de Louvain (UCLouvain) and St. Luc University Hospital. The creation of Novadip was supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II. Using the company's unique 3M3 tissue regeneration platform, which utilizes adipose-derived stem cells within a 3-dimensional... Read More
